Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Gains from Investment Securities (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed Gains from Investment Securities for 5 consecutive years, with $472336.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities rose 6.74% year-over-year to $472336.0, compared with a TTM value of $472336.0 through Sep 2025, up 6.74%, and an annual FY2024 reading of $8.6 million, up 57.09% over the prior year.
  • Gains from Investment Securities was $472336.0 for Q3 2025 at Lucid Diagnostics, up from $274837.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.7 million in Q2 2024 and bottomed at $66921.0 in Q1 2025.
  • Average Gains from Investment Securities over 5 years is $3.3 million, with a median of $2.0 million recorded in 2021.
  • The sharpest move saw Gains from Investment Securities soared 114.56% in 2023, then plummeted 96.86% in 2025.
  • Year by year, Gains from Investment Securities stood at $1.4 million in 2021, then skyrocketed by 80.76% to $2.6 million in 2022, then soared by 114.56% to $5.5 million in 2023, then skyrocketed by 57.09% to $8.6 million in 2024, then plummeted by 94.54% to $472336.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for LUCD at $472336.0 in Q3 2025, $274837.0 in Q2 2025, and $66921.0 in Q1 2025.